Navigation Links
FDA Accepts Tasimelteon New Drug Application For Priority Review In The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:7/29/2013

WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing and granted a priority review classification to Vanda's New Drug Application (NDA) for tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24) in the totally blind.

The FDA grants priority review status for a "drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness" over current therapies[1].  Currently, there is no approved treatment for Non-24 and tasimelteon has the potential to address this unmet medical need.

"We are extremely pleased that the FDA has granted tasimelteon priority review for the treatment of Non-24 in the totally blind," said Mihael H. Polymeropoulos M.D., Vanda's President and Chief Executive Officer.  "The agency's acceptance of the NDA and decision to place tasimelteon in a category of expedited review are important milestones for Vanda as we take another step toward our goal of providing patients with a treatment for Non-24."

The FDA determined the action target date under Prescription Drug User Fee Act (PDUFA-V), to be January 31, 2014.  The FDA has also tentatively scheduled an advisory committee meeting to discuss the tasimelteon application on November 14, 2013.

About Non-24-Hour Disorder
Non-24 is a serious, rare, and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle.  Non-24 affects a majority of totally blind individuals, or between 65,000 and 95,000 people in the U.S.  Non-24 occurs almost entirely in individuals who lack the light sensitivity ne
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
3. FDA Accepts Novens NDA For An Investigational Nonhormonal Therapy For Menopausal Vasomotor Symptoms
4. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
5. Vanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
6. Vanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
7. Vanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
8. Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
9. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
10. EPGL Medical Invents Self Powered Contact Lenses for Medical and Consumer Applications
11. FDA Grants Priority Review To New Drug Application For MNK-795 Submitted By Depomed Licensee Mallinckrodt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The Competitive Intelligence ... and marketplace changes. CI leaders who adjust will succeed, ... In a new Best Practices, LLC study CI leaders ... insights, including: - Use secondary research whenever ... research - Internal staff who are creative ...
(Date:8/29/2014)...   Mast Therapeutics, Inc. (NYSE MKT: ... Santosh Vetticaden, Chief Medical Officer and Senior Vice ... reasons, in mid-September.  Edwin L. Parsley , ... which Mast acquired earlier this year, will assume ... Chief Medical Officer.  Dr. Parsley previously was with ...
(Date:8/29/2014)... Research and Markets has announced ... Report, 2014-2017" report to their offering. ... of reimbursement for medical expenses, the Chinese orthopedic instrument ... presenting a CAGR of 19.2% during 2009-2013. Trauma products, ... of orthopedic instruments in China , ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... - MIV Therapeutics Inc.,(OTCBB:MIVT) (FWB:MIV), a leading ... delivery systems for,cardiovascular stents and other implantable ... sponsored bench test confirmed that,merging Biosync Scientific's ... acquired, with the Company's polymer-free drug,delivery system ...
... to Company Oncology Programs to be Presented, SOUTH ... Incorporated announced,today that four posters containing non-clinical data ... the American Association,for Cancer Research (AACR) to be ... CA. These posters are related to multiple oncology,programs ...
Cached Medicine Technology:MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 2MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 3MIV Therapeutics Announces Pivotal Test Results Further Validating,Company Stent Coatings Meet Critical FDA Fatigue Guidelines 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 2Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 3Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 4Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 5Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 6Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting 7
(Date:8/30/2014)... Hicksville, NY (PRWEB) August 30, 2014 ... Organizations throughout the planet has been one of ... in order to create a positive impact around ... aesthetics and staffed with top trained executives and ... millions of people worldwide. Vital statistics demonstrate ...
(Date:8/30/2014)... New York, New York (PRWEB) August 30, 2014 ... and other incretin mimetic claims continue to move forward ... a statement issued by AstraZeneca PLC on July 31, ... have been named in 409 product liability claims that ... cancer. Court documents indicate that many of these claims ...
(Date:8/30/2014)... AZ (PRWEB) August 30, 2014 Hastings ... personal injury attorneys located throughout Arizona is pleased to ... This is one specific example among many cases where ... clients are able to retain a greater portion of ... after case that providing a positive solution for Arizona ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web ... is now offering discount for Labor Day on ... on putting forward the best of web development technology ... team of professionals and web developers and designers has ... the critical issues of web development and can develop ...
(Date:8/30/2014)... Bethesda, MD (PRWEB) August 30, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
Breaking Medicine News(10 mins):Health News:Cradle of Aviation Museum Opens Its Doors to Long Island Scientologists 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... 12 Blue Cross of California,highly values the trust ... with their physicians and medical groups. It is,our responsibility ... to date,both for the benefit of our members and ... we do this is to send the member,s application ...
... ... New Event Name ... Same Commitment to ... the Health of all Babies, ... pleased to announce that 4-year-old Bradley,Coffey of Kennedy Heights and his family ... Formerly known as WalkAmerica,March for Babies is the March of Dimes premier ...
... Feb. 12 Echo Therapeutics,Inc. (OTC Bulletin Board: ... that it had completed an approximately,$2.3 million private ... VII, LLC and certain other select institutional and ... The $2,292,459 in aggregate principal amount of ...
... 12 Edwards Lifesciences,Corporation (NYSE: EW ), the ... that it has filed a patent infringement lawsuit against,CoreValve, ... Court for,the District of Delaware. The suit seeks injunctive ... family of patents for transcatheter,heart valve technology., "Edwards ...
... DARIEN, Ill., Feb. 12 Darien, IL-based Healthation,announced ... Provider Portal to deliver interactive self-service,capabilities to its ... track record of integrating with the plan,s existing ... claims directly through the,provider portal., The AboveHealth ...
... MENLO PARK, Calif., Feb. 12 XTENT, Inc.,(Nasdaq: ... results for 2007,after market close on Tuesday, February 19, ... day at 2 p.m., Pacific Time (5 p.m. Eastern ... XTENT,s President and Chief,Executive Officer, and Tim Kahlenberg, Chief ...
Cached Medicine News:Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 2Health News:Local Families Chosen for Ambassador Role for 2008 March for Babies 3Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 2Health News:Echo Therapeutics Announces Closing of Approximately $2.3 Million Private Financing 3Health News:Edwards Lifesciences Initiates Patent Infringement Litigation Against CoreValve in the U.S. 2Health News:PrimeWest Health Chooses Healthation's AboveHealth as Next Generation Provider Portal 2
An advanced microprocessor-controlled unit with superior reliability and reproducible power. Its modern electronics provides the precision and control a surgeon expects....
Compressor-cooled plate used to keep blocks cold while sectioning....
Compact instrument that quickly dries racks of slides using warm air....
Liquichek Blood Gas Plus EGL Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2, electrolytes, glucose and lactate (lactic acid)....
Medicine Products: